...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Combination nucleos(t)ide analogue as initial treatment for chronic hepatitis B: Have we put this to rest?
【24h】

Combination nucleos(t)ide analogue as initial treatment for chronic hepatitis B: Have we put this to rest?

机译：联合核苷酸（t）ide类似物作为慢性乙型肝炎的初始治疗：我们是否已安息了？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Combination nucleos(t)ide analogs (NUCs) had been advocated as the initial treatment of chronic hepatitis B when lamivudine and adefovir dipivoxil (ADV) were the only approved NUCs for hepatitis B. These drugs had weak antiviral activity and/or low barrier to resistance with rates of genotypic resistance of 70% and 29%, respectively, after 5 years of continuous treatment. Borrowing from lessons learned in development of treatment for human immunodeficiency virus infection, virologists warned that a combination of NUCs with no cross-resistance would be necessary to maintain long-term suppression of hepatitis B virus (HBV) replication.
机译：当拉米夫定和阿德福韦酯（ADV）是唯一被批准用于乙型肝炎的NUCs时，已提倡联合使用核苷酸（t）-ide类似物（NUCs）作为慢性乙型肝炎的初始治疗。这些药物的抗病毒活性较弱和/或对乙肝的屏障较弱连续治疗5年后，耐药性的基因型耐药率分别为70％和29％。病毒学家警告说，从开发针对人类免疫缺陷病毒感染的疗法中汲取的经验教训，病毒学家警告说，为了长期抑制乙型肝炎病毒（HBV）复制，必须将无交叉耐药性的NUC组合使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号